Covid-19 man­u­fac­tur­ing roundup: Af­ter Emer­gent dis­as­ter, As­traZeneca in talks to move to Catal­ent plant — re­port; Sinopharm says it has ca­pac­i­ty to pro­duce 5B vac­cines

Af­ter months of pro­duc­tion of its vac­cine plagued by a mix­up at a Bal­ti­more Emer­gent plant that has been tak­en over by the FDA, As­traZeneca is in talks with the US gov­ern­ment to move pro­duc­tion to a fac­to­ry owned by Catal­ent, the New York Times re­ports.

The news comes just days af­ter news broke that J&J is ex­pect­ing to an­nounce that the con­t­a­m­i­na­tion prob­lems at the plant have been re­solved and pro­duc­tion is set to re­sume. Emer­gent an­nounced that af­ter a month of the FDA tak­ing over the Bayview site, a laun­dry list of is­sues has been solved, it said in a state­ment. With an agree­ment with the FDA, mil­lions of the dos­es of the J&J vac­cine that were quar­an­tined could be freed up for de­liv­ery and ad­min­is­tra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER